

PATENT

ATTORNEY DOCKET NO. CSHL.005.01US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Malinow *et al*)
Serial No.: 09/353,126) Examiner: S. L. Turner
Filed: July 14, 1999) Art Unit: 1647
For: **DIAGNOSTIC METHODS FOR DRUG**) **INFORMATION DISCLOSURE**
SCREENING FOR ALZHEIMER'S) **STATEMENT TRANSMITTAL**
DISEASE)
)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is:

- An Information Disclosure Statement.
- A PTO-1449.
- Copies of references listed on the PTO-1449 form.
- English translation of foreign language references.
- Copy of foreign examination report.
- English translation of foreign examination report.
- Return postcard (postage prepaid).


CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on February 12, 2001

Signed



Printed



1. This Information Disclosure Statement is filed before the later of:
- three months from the filing date of this national application;
- three months from the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or
- the mailing date of a first office action on the merits.
- In accordance with 37 C.F.R. § 1.97(b), no fee is required.
2. This Information Disclosure Statement is filed after the events noted in paragraph 2, but before either:
- (1) a final action under 37 C.F.R. § 1.113; or
- (2) a Notice of Allowance under 37 C.F.R. § 1.311.
- In accordance with 37 C.F.R. § 1.97(c) also enclosed is:
- a fee under 37 C.F.R. § 1.17(p) in the amount of \$210; or
- a certification as stated below.
3. This Information Disclosure statement is filed before the payment of the issue fee, but after either:
- (1) a final action under 37 C.F.R. § 1.113; or
- (2) a Notice of Allowance under 37 C.F.R. § 1.311.
- In accordance with 37 C.F.R. § 1.97(d) also enclosed is:
- (1) A certification, as stated below;
- (2) A Petition requesting consideration of the Information Disclosure Statement; and
- (3) The petition fee set forth in 37 C.F.R. § 1.17(i)(1) in the amount of \$180.

Certification

The undersigned also states:

- [] Each item of information contained in the Information Disclosure Statement cited herein was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or
- [] No item of information contained in the Information Disclosure Statement submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of this Information Disclosure Statement.

The fees indicated above are:

TOTAL FEES: \$ 180

- [X] For fees, see Transmittal Letter
- [] A check including the amount of the above-indicated TOTAL FEES is attached.
- [] Please charge Deposit Account No. 18-0020 in the amount of: \$ _____.
- [] A check in the amount of \$ _____ is attached.
- [] No fee is required.
- [X] The Commissioner is hereby authorized to charge any underpayment of the following fees associated with this communication, including any necessary fees for extension of time, or credit any overpayment to Deposit Account No. 18-0020.
 - [X] Any filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims.
 - [X] Any patent application processing fees under 37 C.F.R. § 1.17.
 - [X] A duplicate copy of this sheet is attached for accounting purposes.

Respectfully submitted,


Dated: February 12, 2001

Barbara Rae-Venter
Barbara Rae-Venter, Ph.D.
Reg. No. 32,750

Rae-Venter Law Group, P.C.
P.O. Box 60039
Palo Alto, CA 94306-0039
Telephone (650) 328-4400
Facsimile (650) 328-4477

BRV/mwy

PATENT



ATTORNEY DOCKET NO. CSHL.005.01US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Malinow *et al*)
Serial No.: 09/353,126) Examiner: S. L. Turner #4
Filed: July 14, 1999) Art Unit: 1647 A.QJ
For: DIAGNOSTIC METHODS FOR DRUG) INFORMATION DISCLOSURE
SCREENING FOR ALZHEIMER'S) STATEMENT
DISEASE)

2/23/01

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is hereby submitted in accordance with 37 CFR 1.98 and pursuant to Applicant's continuing duty under 37 CFR 1.56 to bring any information which may be material to patentability of this application to the Examiner's attention.

References C8-17 have been submitted by the Applicants in priority Application No. 09/193,221. Each of these references have been cited by or submitted to the Office in a properly identified prior application; therefore, under 37 C.F.R. §1.98(d) copies of these references are not required.

CERTIFICATE OF FIRST CLASS MAILING

02/20/2001 RHARIS1 00000054 09353126
02 FC:126 180.00 OP

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on February 12, 2001

Signed

Printed


Jeffrey M. Libby

Applicant makes no representation that a complete search has been conducted by the Applicant, or that there is not possibly more relevant art. Applicant also makes no representation that the information submitted herewith is in fact material.

The subject application is believed patentable over any of the above references.

Respectfully submitted,

Dated: February 12, 2001




Barbara Rae-Venter, Ph.D.
Reg. No. 32,750

RAE-VENTER LAW GROUP, P.C.
P.O. Box 60039
Palo Alto, CA 94306-0039
Telephone (650) 328-4400
Facsimile (650) 328-4477

BRV/JML

PATENT



DOCKET NO. CSHL.005.01US

COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Sheet 1 of 2

In re application of: Malinow *et al.*] Art Unit: 164 *F*
Serial No.: 09/353,126] Examiner: S. L. Turner
Filed: July 14, 1999]

U.S. PATENT DOCUMENTS

<u>Ref. Desig.</u>	<u>Examiner's Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
				<u>None</u>		

FOREIGN PATENT DOCUMENTS

<u>Ref. Desig.</u>	<u>Examiner's Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
				<u>None</u>		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Examiner's
Desig. Initials


- C8 Bliss *et al.* (1993) Nature 361:31-39.
C9 Borchelt *et al.* (1996) Neuron 17: 1005 – 1013.
C10 Evans, *et al.* (1996) Neuropharmacology 35: 347-357.
C11 Fastbom *et al.* (1998) Alzheimer Dis Assoc. Disord. 12: 14-17.
C12 Guo *et al.* (1996) Neuroreport. 8: 379-383.

Examiner: No references presented Date Considered:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PATENT

DOCKET NO. CSHL.005.01US



COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Sheet 2 of 2

In re application of: Malinow *et al.*] Art Unit: 1645
] Examiner: S. L. Turner

Serial No.: 09/353,126]

Filed: July 14, 1999

- C13 Muir *et al.* (1996) J. Cereb. Blood Flow Metab. (16): 1211-1218.
C14 Ohkuma *et al.* (1994) Jpn. J. Pharmacol 64:125-128.
C15 Shen, *et al.* (1997) Cell 89: 629-639.
C16 Wigstrom *et al.* (1986) J. Physiol. (Paris) 81: 228-236.
C17 Wong *et al.* (1997) Nature 387: 288-292.

Examiner:

Date Considered:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.